Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 586 to 600 of 1136 results for pain

  1. Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (TA101)

    Evidence-based recommendations on docetaxel for treating hormone-refractory metastatic prostate cancer in adults.

  2. Fasciotens for abdominal wall closure (MIB321)

    NICE has developed a medtech innovation briefing (MIB) on fasciotens for abdominal wall closure .

  3. Hospital care

    NICE's impact on hospital stays, delays in leaving hospital and independent living

  4. Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma in adults who have not had ipilimumab.

  5. Optowire for measuring fractional flow reserve (MIB199)

    NICE has developed a medtech innovation briefing (MIB) on Optowire for measuring fractional flow reserve .

  6. Photodynamic endometrial ablation (IPG47)

    Evidence-based recommendations on photodynamic endometrial ablation. This involves using a light-sensitive chemical and laser to destroy the endometrium.

  7. Prosthetic intervertebral disc replacement in the cervical spine (IPG341)

    Evidence-based recommendations on prosthetic intervertebral disc replacement in the cervical spine. This involves removing the damaged disc and inserting an artificial disc in its place.

  8. MRI guided focussed ultrasound for chronic pain

    Discontinued [GID-IP1043]

  9. Palliative photodynamic therapy for advanced oesophageal cancer (IPG206)

    Evidence-based recommendations on palliative photodynamic therapy for treating advanced oesophageal cancer. This involves injecting a photosensitising agent into the tumour and using light to activate it and destroy the tumour cells.

  10. Type 1 diabetes in adults (QS208)

    This quality standard covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It describes high-quality care in priority areas for improvement.

  11. Powered microdebrider turbinoplasty for inferior turbinate hypertrophy (IPG498)

    Evidence-based recommendations on powered microdebrider turbinoplasty for inferior turbinate hypertrophy. This involves cutting away some of the swollen membrane covering the turbinates.

  12. Percutaneous radiofrequency ablation for renal cancer (IPG353)

    Evidence-based recommendations on percutaneous radiofrequency ablation of renal cancer. This involves using heat produced through electrodes placed into the tumour to destroy the cancer cells.

  13. Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA275)

    Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

  14. Etelcalcetide for treating secondary hyperparathyroidism (TA448)

    Evidence-based recommendations on etelcalcetide (Parsabiv) for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis.

  15. Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)

    Evidence-based recommendations on aflibercept (Eylea) for treating visual impairment caused by macular oedema after branch retinal vein occlusion.